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Editor:
We read with interest the review by Dr 
Sheedy and colleagues in the March 
2017 issue of Radiology (1), as it sum-
marizes magnetic resonance (MR) imag-
ing of perianal Crohn disease (CD) from 
tip to toe in a brilliant educational form.
The MR imaging protocol described 
by the authors includes contrast-en-
hanced T1-weighted imaging with fat 
saturation in all patients except those 
with poor renal function. Horsthuis et 
al (2) demonstrated in 2009 the useful-
ness of contrast-enhanced MR imaging 
for determining disease activity. Con-
trast agent administration is also re-
quired in case of suspicion of neoplastic 
tissue complicating fistulas. The joint 
European Crohn’s and Colitis Organisa-
tion–European Society of Gastointesti-
nal and Abdominal Radiology guidelines 
(3) report that T2-weighted images and 
contrast-enhanced T1-weighted images 
are included in the MR imaging proto-
col for the evaluation of perianal CD.
However, as we have demonstrated 
(4), an axial T2-weighted fast spin-
echo sequence with fat saturation, in 
particular the short inversion time in-
version-recovery (STIR) sequence, is 
a valid alternative to postcontrast T1-
weighted fat-saturated imaging, allow-
ing the identification of the primary 
fistula and any secondary ramification.
Moreover, the Van Assche 
classification (5), also reported by Dr 
Sheedy and colleagues, does not take 
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We thank Dr Vernuccio and colleagues 
for their interest in our study. Because 
of its morbidity and high relapse rates, 
substantial efforts to treat patients with 
perianal CD are warranted (1–3). Our 
belief in improved interdisciplinary un-
derstanding of advances in imaging and 
surgical and medical treatment moti-
vated our review (4).
We are aware of the recent contro-
versy regarding gadolinium retention 
(5), especially with the use of linear 
as opposed to macrocyclic GBCAs, and 
appreciate your highlighting this issue 
in patients with perianal CD, who are 
likely to undergo repeat imaging.
into account the contrast enhancement 
for grading disease activity. It has also 
been demonstrated that disappearance 
of T2 hyperintensity correlates with 
the clinical benefit of maintenance an-
titumor necrosis factor α therapy (6).
Dr Sheedy and colleagues (1) state 
that figure 4 demonstrates the “bene-
fit of gadolinium-based contrast mate-
rial in perianal imaging,” showing that 
the contrast agent demonstrates only 
enhancing granulation tissue within the 
fistula. However, the granulation tis-
sue can also be demonstrated for its 
hyperintensity on T2-weighted images, 
and its reduction is demonstrated by 
the loss of this hyperintensity, so that, 
as also stated by Dr Sheedy and col-
leagues, loss of gadolinium enhance-
ment generally parallels loss of T2 sig-
nal intensity during healing.
Considering the costs and the re-
cently reported potential risks of some 
gadolinium-based contrast agents (GB-
CAs) (7,8), we believe that intrave-
nous injection of a GBCA could be 
performed in the first MR imaging as-
sessment of perianal CD or in case of 
doubts in the precontrast sequences. 
However, the definitive role of GBCA in-
jection in perianal CD must be clarified 
with further studies to fully understand 
the clinical-radiologic settings requiring 
its administration.
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We appreciate their important re-
port (6), which concludes that the STIR 
sequence is a valid alternative to post-
contrast T1-weighted fat-saturated im-
aging, allowing the identification of the 
primary fistula and any secondary ram-
ification. We agree that fistula charac-
terization can be carried out with T2-
weighted sequences alone and that 
healing fistulas decrease in T2 hyperin-
tensity (as well as size and complexity). 
As they acknowledge, their small study 
may be underpowered to address the 
potential miss rate of small undrained 
abscesses, but, importantly, they found 
that STIR imaging helped identify nine 
of nine abscesses. Because “postcon-
trast T1-weighted images are used for 
identifying abscesses” (4), this is the 
central issue to consider when using 
GBCAs in these patients (4,7). The de-
tection of small abscesses has profound 
ramifications for patient care when the 
patient will be treated only medically 
(eg, with biologic agents), as antibiotic 
treatment is mandatory; for surgical 
patients, much of the benefit in the MR 
examination itself is identification of ab-
scesses that are surgically occult (8).
With this information—how can we 
best serve our patients? We advocate 
for immediate conversion to macrocy-
clic agents, which appear safer. Further 
research and confirmation of their find-
ings would be useful, and we intend to 
add STIR imaging to our routine peri-
anal MR imaging protocol. In patients 
with suspected fistula, there may be no 
need to administer GBCAs if no peri-
anal fistula is detected. In patients who 
have previously undergone imaging, 
if the primary fistula and its ramifica-
tions are all decreasing in size and T2-
weighted hyperintensity, the yield of 
GBCA administration is likely low and 
it may be reasonable to skip contrast 
material administration; more research 
is needed. In other scenarios and rou-
tine clinical care, however, we intend to 
continue to utilize macrocyclic GBCAs 
until additional evidence and experi-
ence is gained, as identification of small 
abscesses changes clinical management 
for medical and surgical therapies.
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In an early online edition, the arti-
cle title should have read as follows: 
Detection of Bone Marrow Edema in 
Nondisplaced Hip Fractures: Utility of 
a Virtual Noncalcium Dual-Energy CT 
Application.
This has been corrected online and 
in print.
